Gongyanqing Solution veterinary-grade API is handled as a liquid process stream in which the active fraction is already dissolved or suspended in a solvent system. This physical form removes dry-milling and dry-micronisation steps from downstream manufacturing but introduces solvent partitioning, viscosity, water activity, and evaporation-front variables into each dosage-form route. Verification of the batch-specific certificate of analysis against the intended route must include assay on an as-is basis, related substances, residual solvents under VICH GL18, and microbiological screening consistent with Ph. Eur. 5.1.4 or USP 61/62 where applicable. Specific batch instructions must be qualified against the approved marketing authorisation file; published route-specific data for Gongyanqing Solution are limited in public monographs, and the following process windows represent industrial starting points that require confirmation by batch-scale trials. The seven downstream tracks are separated by dominant unit operation and by the different critical process parameters that arise when a liquid API is sprayed, mixed, dried, encapsulated, sterilised, or diluted into a finished veterinary medicine.

For parenteral veterinary formulations, the liquid feed is typically transferred from 316L stainless steel holding vessels with internal surface finish Ra ≤ 0.45 µm through a 0.22 µm sterilising-grade polyvinylidene difluoride membrane before aseptic filling under ISO 14644-1 Grade A laminar-flow protection. Terminal sterilisation may be substituted only when forced-degradation data demonstrate that the solution can withstand an F0 ≥ 15 min at 121 °C; otherwise aseptic filtration followed by blow-fill-seal is evaluated. Each batch is adjusted to an osmolality of 280–320 mOsm/kg and a pH window bracketed by the stability profile in the dossier; pH drift above ±0.3 units during storage indicates buffer-capacity failure. Filled vials and ampoules are inspected for visible particles at 2,500–3,000 lux against Ph. Eur. 2.9.20 and for container-closure integrity using vacuum decay per ASTM F2338-09. The liquid API introduces a solvent-residue boundary: if the solution contains propylene glycol or glycerol, the injection must document residual solvent levels under VICH GL18 and establish the metabolic load for each target species, particularly in neonatal ruminants where hepatic glucuronidation is immature. Bulk solution holding time in stainless steel tanks is limited by mixing validation and bioburden control; preserved bulk solutions are not standard for injectables, and transfer lines are sanitised by clean-in-place with 1–2% w/w sodium hydroxide at 60–75 °C. The terminal container is chosen only after extractable and leachable profiling under Ph. Eur. 3.2.9 and USP 661.1 to rule out rubber stopper migration into the finished injection.

At Which Moisture Addition Level Does the Solution API Stop Acting as a Binder and Begin Causing Tablet Lamination?

When the solution is used as the binder phase in high-shear wet granulation, a systematic screening is run on a granulator with bowl capacity from 25 L to 600 L and impeller tip speed of 4–8 m/s. The liquid solution is added through a pressure nozzle at a rate that keeps the wet mass moisture content in the range 8–14% w/w for a lactose monohydrate and microcrystalline cellulose matrix; viscosity of the API solution between 5 and 50 mPa·s at 25 °C determines whether the nozzle must be changed from a flat-fan to a hollow-cone pattern to prevent local overwetting. The granulation endpoint is not judged visually but by impeller power draw and thermal conductivity: a power increase of 15–25% above the dry-blend baseline marks granule consolidation, while conductivity probes record a sharp rise when the continuous liquid-bridge network forms. Wet granules are milled through a 1.5–2.0 mm screen and dried in a fluid bed to a final loss-on-drying of 2–4% w/w, checked by Karl Fischer titration if the solution is hygroscopic. Compression is performed on a rotary tablet press with precompression force set at 20–30% of main compression force, main compression force held within 6–14 kN, and turret speed limited to 30–60 rpm to control elastic recovery of granules containing residual non-volatile solvent. Tablet hardness is targeted at 40–80 N depending on tablet diameter, and disintegration is confirmed according to Ph. Eur. 2.9.1 or USP 701 with water at 37 ± 2 °C. When lamination appears at moisture levels above 14% w/w or when the liquid API contains a co-solvent such as ethanol, the granulation endpoint must be shifted to lower power draw values; the dry granulation bypass using roller compaction should be rejected unless a solvent-free binder is introduced. Tablets intended for oral administration to dogs or cats must meet 21 CFR 211.166 chemical stability requirements and dose uniformity via USP 905; for a 200 mg tablet, a content-uniformity acceptance value ≤ 15.0 for 10 units is a release limit.

Shell Plasticiser Partitioning Controls Liquid-Filled Hard Capsule Stability

Under semi-automatic banding systems operating at 35–45 °C, the API solution is filled into hard gelatin or HPMC capsules with a fill volume that is 80–90% of the capsule-body capacity to accommodate thermal expansion during banding. The primary stability risk is migration of low-molecular-weight solvent from the fill into the shell; this migration alters shell water distribution and can produce brittle fracture at the cap-body junction when equilibrium relative humidity falls below 40% RH. Capsule fill formulations are therefore pre-conditioned with plasticiser screening across a matrix of glycerol, sorbitol-sorbitan, and medium-chain triglycerides; differential scanning calorimetry on the shell is used to track melting-endotherm depression from absorbed solvent, and thermogravimetric analysis is used to measure shell moisture loss from 25 °C to 120 °C. For a hard gelatin shell, shell moisture content between 13% and 16% w/w is required to prevent cracking; for HPMC shells, the acceptable moisture range is broader but still bounded by stickiness above 18% w/w. Liquid-filled hard capsules intended for veterinary oral administration are sealed with an aqueous gelatin band of 40–50 mm width on a Qualicaps or Capsugel banding machine, and seal strength is verified by burst testing at 0.8–1.2 bar; leakers are rejected by vision systems with 0.1 mm defect resolution. Dissolution is run in 900 mL of 0.01 N hydrochloric acid per USP 711 with paddle speed 50 rpm; the API solution’s high miscibility can cause early release, so an in situ precipitation step is sometimes introduced by adding croscarmellose sodium at 3–6% w/w to the fill. 21 CFR 211.166 and Ph. Eur. 2.9.3 require that the dissolution method be discriminating for capsule shell rupture and fill spreading, not solely for active dissolution. Capsule-conditioning rooms are controlled at 40–50% RH and 15–20 °C because rapid shell drying after banding is a common cause of dimpling and weak band adhesion.

High-shear mixing of the liquid API with porous lactose carriers produces a moisture redistribution front that governs final blend homogeneity and flow. In a 500–2,000 L ribbon blender or a ploughshare mixer with high-speed choppers, the solution is sprayed through a twin-fluid nozzle at an atomising pressure of 1.5–3.0 bar; the carrier-bed temperature is maintained between 20 °C and 25 °C to avoid solvent evaporation before distribution. The sequence starts with a lactose monohydrate carrier of D50 150–250 µm, to which 1.0–2.0% w/w colloidal silicon dioxide is added as glidant and moisture scavenger; the API solution is sprayed over 10–20 min at a rate calibrated to the solution viscosity, and the loaded carrier is then blended for an additional 5–10 min with chopper engagement at 1,500–3,000 rpm. Blend-uniformity release testing follows USP 905 using 10 stratified powder samples; a relative standard deviation ≤ 5.0% is considered a minimum for oral powder sachets, while a more stringent ≤ 2.5% RSD is applied when the powder is further dispersed in drinking water at 1 g/L to 10 g/L. Sieve analysis is conducted using ISO 3310-1 sieves to confirm no agglomerates larger than 850 µm, because agglomerates above this diameter block nipple drinkers in poultry houses. The finished powder is packed in aluminium-foil sachets with moisture vapour transmission rate ≤ 0.1 g/m²·24 h at 38 °C and 90% RH per ASTM F1249, and fill weight is checked on a checkweigher with a tolerance of ±1.0% for sachets from 100 g to 1 kg.

Inside Fluid-Bed Granulation: Spray Rate Windows and Moisture Analyser Feedback

Top-spray fluidised-bed granulators with batch sizes of 100–500 kg require the API solution to be atomised through a binary nozzle at air pressure 2.0–4.0 bar; the inlet-air temperature is held at 60–75 °C, while the product-bed temperature is maintained at 28–35 °C by adjusting inlet humidity. Spray rate is the critical parameter because the liquid API solution has a fixed solids content and any increase above the evaporation capacity of the bed produces defluidisation and wet quenching. Process control uses near-infrared moisture analysers calibrated against Karl Fischer titration on samples taken at 5-minute intervals; a moisture set point of 10–15% w/w during spraying is followed by a drying ramp that drops moisture to 3–5% w/w within 20–40 min. Granule porosity is tracked by mercury intrusion porosimetry; intragranular pore volume of 0.15–0.35 cm³/g is associated with acceptable tabletability, while porosity above 0.45 cm³/g yields over-granulated, low-density granules that fracture under compression. The final granules are sized through a 1.0–2.0 mm screen and compressed as described in the tablet track; granules that survive the fluid-bed process should have a bulk density of 0.45–0.60 g/mL and a compressibility index below 20% per Ph. Eur. 2.9.34. When the fluid-bed granulation route is used for veterinary premix intermediates, the same granules are further blended with mineral carriers and not compressed, so acceptance criteria shift to dustiness index measured by a rotating-drum tester with a value below 2 mg/kg against a cashmere dust reference. Defluidisation due to spray-rate overrun is recoverable only by partial discharge of the bowl and manual screening; the process is therefore fitted with differential-pressure transmitters across the distributor plate to alarm at +30% above baseline bed-pressure drop.

Veterinary Premix Dilution Geometry and Carryover Control

In medicated feed premix lines, the solution is applied by low-pressure spray nozzles onto a mineral or organic carrier in a horizontal paddle mixer; the carrier is typically calcium carbonate, sepiolite, or maize starch with an oil-absorption number between 30 and 60 g/100 g per ASTM D281. The liquid solution is metered into the mixer at 2–8% w/w relative to carrier mass over 10–30 min; at higher loadings, wet spots appear on mixer walls and the coefficient of variation of active distribution across 20 sampling points climbs above 10% CV. The resulting premix is discharged through a 2.0 mm aperture screen and packed in paper-plastic valve bags; analytical verification is performed by HPLC using a validated method with a limit of quantification low enough to detect carryover at the target withdrawal period. Under 21 CFR 225.20 and 21 CFR 225.30, medicated feed mills must document flush sequences, and the rinse material used after a Gongyanqing-containing batch is assayed to ensure that carryover into non-target feed remains below the limits set in the Type A medicated article approval. A carryover limit of 1.0% of the lowest approved dose in the target species is used as a default release criterion in some jurisdictions, but the binding value must be taken from the specific marketing authorisation. The premix is then diluted into final feed at 1–25 kg/tonne depending on dose; because the API is present as a liquid-loaded solid, segregation can occur in bin discharge if the particle-size difference between carrier and ground grain exceeds 300 µm, so the final feed mixing time in a horizontal ribbon mixer is extended to 10–15 min and the mixer is filled to 60–80% of gross volume. Quality audits require that the feed mill maintain cleanout protocols that are validated by marker residue testing, not by visual inspection alone.

Direct oral drench formulations introduce the API solution into a buffered, preserved vehicle at high dilution. The compounding tank is charged with purified water at 40–50 °C, then buffered with citrate or phosphate to a pH in the range 4.0–6.5; the solution is added under low-shear propeller mixing at 100–300 rpm to avoid foaming. Preservatives are selected by antimicrobial preservative-effectiveness testing per Ph. Eur. 5.1.3 or USP 51; a typical challenge matrix includes sodium benzoate at 0.1–0.2% w/w and potassium sorbate at 0.1–0.2% w/w, but the exact level is adjusted by challenge tests against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. The final solution is clarified through a 1.0 µm prefilter and a 5 µm guard filter before filling into high-density polyethylene jerry cans or amber polyethylene terephthalate bottles; packaging is selected by light-transmission data measured over 250–450 nm. Dissolved oxygen is controlled below 0.5 mg/L by nitrogen sparging if the active molecule has an oxidation-sensitive catechol or thioether moiety; headspace oxygen in the filled bottle is limited to less than 2% by volume. Stability samples are stored at 25 °C/60% RH, 30 °C/65% RH, and 40 °C/75% RH with pH, assay, and related substances checked at 0, 1, 2, 3, and 6 months; batch rejection is driven by related substances exceeding the specification, not by assay drift alone. The oral solution is not interchangeable with the injectable grade unless the solvent composition and microbial-risk profile are explicitly bridged in the marketing authorisation dossier.